Taysha Gene Therapies, Inc. Common Stock TSHA
Analyst Ratings
- Consensus
- Buy — 11 Buy · 0 Hold · 0 Sell (11 analysts)
- Avg. Price Target
- $12.80 (+211.4% upside)
Key Stats
- Today's Range
- $3.89 – $4.13
- 50-Day Range
- $3.46 – $6.75
- 52-Week Range
- $2.71 – $7.30
- Volume
- 356K shs
- Average Volume
- 4.36 million shs
- Market Cap
- $1.28 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.08%
- Days to Cover
- 1.00
About Taysha Gene Therapies, Inc. Common Stock
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Related Stocks
Compare head-to-head: TSHA vs AMGN·TSHA vs MRNA·TSHA vs HALO·TSHA vs RGEN
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.